NCT06098625View on ClinicalTrials.gov

Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus

NANot yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

July 1, 2025

Study Completion Date

December 1, 2025

Conditions
Diabetes MellitusKidney Transplant; Complications
Interventions
DRUG

Empagliflozin 25 MG

Empagliflozin 25 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus

DRUG

Linagliptin 5 mg Oral Tablet

linagliptin 5 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus

All Listed Sponsors
lead

Medanta, The Medicity, India

OTHER

NCT06098625 - Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus | Biotech Hunter | Biotech Hunter